Compounds > mdl 100240
Page last updated: 2024-09-04

mdl 100240 and Hypertension

mdl 100240 has been researched along with Hypertension in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's6 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agabiti-Rosei, E; Bova, S; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP1
Rossi, GP1
Agabiti-Rosei, E; Bianchi, R; De Ciuceis, C; Nussdorfer, GG; Paiardi, S; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, L; Rossi, GP; Sleiman, I; Sticchi, D1
Barrett, JS; Haskell, LP; Martin, NE; Pfister, M1
Belloni, AS; Guidolin, D; Nussdorfer, GG; Pessina, AC; Rossi, GP; Seccia, TM; Sticchi, D1
Bennett, T; Brunner-Ferber, F; Gardiner, SM; Kemp, PA1
Agabiti-Rosei, E; Bova, S; Neri, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP; Sacchetto, A1

Reviews

1 review(s) available for mdl 100240 and Hypertension

ArticleYear
Dual ACE and NEP inhibitors: a review of the pharmacological properties of MDL 100240.
    Cardiovascular drug reviews, 2003,Spring, Volume: 21, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Biological Availability; Cardiovascular Diseases; Endopeptidases; Humans; Hypertension; Kidney; Prodrugs; Protease Inhibitors; Pyridines

2003

Trials

1 trial(s) available for mdl 100240 and Hypertension

ArticleYear
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
    Journal of clinical pharmacology, 2004, Volume: 44, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biomarkers; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Humans; Hypertension; Models, Biological; Neprilysin; Pyridines

2004

Other Studies

6 other study(ies) available for mdl 100240 and Hypertension

ArticleYear
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
    Journal of hypertension, 2002, Volume: 20, Issue:7

    Topics: Adrenomedullin; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Heart; Hypertension; Male; Models, Cardiovascular; Neprilysin; Organ Size; Peptides; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Severity of Illness Index; Systole; Treatment Outcome; Vasoconstrictor Agents

2002
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.
    Journal of hypertension, 2004, Volume: 22, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Bradykinin Receptor Antagonists; Disease Models, Animal; Drug Interactions; Hypertension; Immunohistochemistry; Male; Matrix Metalloproteinases; Mesenteric Arteries; Myography; Neprilysin; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Resistance; Vasoconstriction

2004
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
    Journal of hypertension, 2006, Volume: 24, Issue:7

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Benzazepines; Creatinine; Fibrosis; Hypertension; Kidney; Male; Neprilysin; Pyridines; Ramipril; Rats; Receptor, Bradykinin B2

2006
Comparative effects of the dual metallopeptidase inhibitor, MDL 100,240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats.
    British journal of pharmacology, 1997, Volume: 122, Issue:8

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Enalaprilat; Hemodynamics; Hypertension; Male; Metalloendopeptidases; Protease Inhibitors; Pyridines; Rats

1997
MDL 100240.
    Drugs in R&D, 1999, Volume: 1, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Dogs; Drugs, Investigational; Endopeptidases; Heart Failure; Humans; Hypertension; Protease Inhibitors; Pyridines; Rats; Rats, Inbred SHR

1999
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.
    American journal of hypertension, 2002, Volume: 15, Issue:2 Pt 1

    Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Aorta; Benzazepines; Blood Pressure; Body Weight; Cardiovascular Diseases; Hypertension; In Vitro Techniques; Male; Neprilysin; Organ Size; Pyridines; Ramipril; Rats; Vasoconstriction

2002